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The ORF45 gene of Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a multifunctional tegument
protein. Here, we characterize the transcriptional control of the ORF45 gene and show that its promoter
can be activated by ORF50 protein, a latent-lytic switch transactivator. The ORF45 promoter can also be
induced by sodium butyrate (SB), a histone deacetylase inhibitor, in the absence of ORF50 protein.
Although SB induces the ORF45 gene independently of ORF50, its full activation may require the presence
of ORF50. Deletion and point mutation analyses revealed that two RBP-Jκ-binding sites in the ORF45
promoter confer the ORF50 responsiveness, whereas NF-Y and Sp1-binding sites mediate the response to
SB. Direct binding of NF-Y, Sp1, or RBP-Jκ protein to the ORF45 promoter is required for the promoter
activation induced by SB or by ORF50. In conclusion, our study demonstrates both ORF50-dependent and
ORF50-independent transcriptional mechanisms operated on the activation of the ORF45 gene.
& 2013 Elsevier Inc. All rights reserved.Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV), also known as
human herpesvirus 8, is associated with at least three malignan-
cies including Kaposi's sarcoma, primary effusion lymphoma (PEL)
and multicentric Castleman's disease (Cesarman et al., 1995; Chang
et al., 1994; Soulier et al., 1995). Like all herpesviruses, KSHV
exhibits two distinct phases of its life cycles, latency and lytic
replication (Miller et al., 1997; Renne et al., 1996). Both latent and
lytic replication cycles are essential for the long-term persistence
of the virus, and multiple gene products expressed from both
programs have been implicated in the pathogenesis of KSHV-
associated diseases (Dourmishev et al., 2003). Although the
physiological stimuli that initiate the KSHV switch between
latency and lytic replication are not fully understood, several
environmental or chemical inducers have been reported to trigger
the lytic reactivation in the latently infected cells. These inducers
include sodium butyrate (SB), 12-O-tetradecanoylphorbol-13-acet-
ate (TPA), hypoxia, endoplasmic reticulum stress, reactive oxygen
species, epinephrine, norepinephrine and proinﬂammatoryll rights reserved.
hen).cytokines as well as superinfection with other viruses (Chang
et al., 2000, 2005a; Dalton-Grifﬁn et al., 2009; Davis et al., 2001;
Lu et al., 2005; Lukac et al., 1999; Miller et al., 1997; Ye et al., 2011).
During KSHV reactivation from latency, the lytic-cycle genes
are expressed in an orderly fashion and can be classiﬁed into three
categories: immediate-early (IE), early and late genes (Miller et al.,
1997; Sun et al., 1999). The IE genes are expressed at the earliest
stage and are resistant to cycloheximide treatment. Zhu et al.
(1999) have identiﬁed four major IE transcripts expressed in
KSHV-infected PEL cells after SB treatment, including (i) a 3.6-kb
or 4.3-kb ORF50-encoding transcript, (ii) a 1.7-kb ORF45-encoding
transcript, (iii) a 2.0-kb transcript carrying ORF4.2, K4.1 and K4,
and (iv) a 4.5-kb transcript that is partially complementary to
ORF29. Especially, the gene products encoded by the ORF50- and
ORF45-containing IE transcripts are multifunctional proteins that
exhibit diverse capacities to modulate the expression of viral or
host genes which facilitate later stages of lytic replication
(Dourmishev et al., 2003).
The ORF50 protein, or called Rta (replication and transcription
activator), is a key regulator for the switch from viral latency to
lytic replication (Sun et al., 1998, 1999). It is a potent transcrip-
tional activator that contains an N-terminal basic DNA-binding
domain and a C-terminal acidic activation domain (Chang and
Miller, 2004; Chang et al., 2002; Wang et al., 2001). Ectopic
P.-J. Chang et al. / Virology 442 (2013) 38–50 39expression of ORF50 protein alone in latently KSHV-infected cells
is sufﬁcient to disrupt viral latency and activates the lytic-cycle
cascade to completion (Gradoville et al., 2000; Lukac et al., 1998).
Furthermore, genetic knockout of the ORF50 gene in a bacmid
containing the KSHV genome has demonstrated the importance of
ORF50 protein in viral reactivation (Xu et al., 2005). Although
ORF50 protein speciﬁcally binds to a deﬁned DNA sequence, direct
DNA binding is not the only mechanism to activate its downstream
target genes (Guito and Lukac, 2012). At least two types of ORF50
response elements (ORF50 REs) have been identiﬁed in the ORF50-
responsive gene promoters (Chang et al., 2005b; Liang et al.,
2002). The ﬁrst type of the ORF50 REs is found in the PAN and
K12 promoters, which contains a highly conservative core
sequence, 5′-AAATGGGTGGCTAACC-3′ (Chang et al., 2002; Song
et al., 2002). Direct binding of ORF50 protein to the PAN/K12
element strongly correlates with the promoter activation by
ORF50. The second type of the ORF50 REs encompasses an RBP-
Jκ-binding site, 50-GTGGGAA-30, which is found in a subset of
early-lytic gene promoters. These ORF50-regulated early-lytic
genes include its own gene, ORF57, K8, K9 (vIRF), ORF21, K3, K5,
K6 (vMIP-1), ORF6, K14 (vOX-2), ORF74 (vGPCR), K2 (vIL-6),
ORF59, ORF61, ORF47 and ORF46 (Chang et al., 2005b, 2010;
Liang et al., 2002; Liang and Ganem, 2003, 2004; Liu et al.,
2008; Wang et al., 2010, 2012; Wang and Yuan, 2007). The
ORF50 protein could not directly bind to the RBP-Jκ-containing
sequence. Activation of these target gene promoters by ORF50
requires the involvement of cellular RBP-Jκ protein, which acts as
an adapter to mediate the indirect access of ORF50 protein to the
target DNA. Mutations at RBP-Jκ-binding sites in these target geneORF45
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Fig. 1. Transcriptional mapping of the ORF45 gene. (A) Schematic diagram of the ORF47
nucleotide positions of the KSHV genome. Arrows represent the 50 transcriptional start s
core promoter region was also shown in the diagram. (B) RACE analysis of the ORF45 ge
used for RACE analysis. The ampliﬁed PCR products corresponding to the 5′ region and
293T cells. Full-length ORF45 cDNA contains a small upstream open reading frame (uOR
FLAG-tag DNA sequences was transfected into 293T cells. After 48-h post-transfection,
antibody. (D) Expression of the endogenous or transfected ORF45 protein in HH-B2 cells.
ORF45-expressing plasmid were subjected to Western blot analysis with anti-ORF45 anpromoters or lack of RBP-Jκ protein in cells will lead to loss of the
ORF50 responsiveness. Besides acting as a transcriptional factor,
ORF50 protein also functions as a replication factor in directing the
assembly of viral DNA replication complexes (AuCoin et al., 2004;
Wang et al., 2004).
The ORF45 protein is a phosphorylated tegument protein of
virion and plays critical roles in the primary viral infection and in
viral lytic replication (Zhu et al., 2002, 2006; Zhu and Yuan, 2003).
During the primary infection, the tegument protein ORF45
released from virions modulates host antiviral responses by
interacting with interferon regulatory factor 7 (IRF-7) (Sathish
et al., 2011; Zhu et al., 2002). The interaction between ORF45
and IRF-7 blocks the phosphorylation and nuclear translocation of
IRF-7, which consequently prevents the activation of type I
interferon (IFN-α/β) genes in response to viral infection. The
ORF45 gene is not expressed in latently KSHV-infected cells
until the lytic induction (Zhu et al., 1999). Upon the lytic induction,
the expressed ORF45 protein forms complexes with p90
ribosomal S6 kinase (RSK) and extracellular signal-regulated
kinase (ERK), which causes activation of both RSK and ERK
(Kuang et al., 2008, 2009). Recently, Kuang et al. (2011) have
shown that the ORF45-mediated ERK/RSK signaling induces
the phosphorylation of eukaryotic translation initiation
factor 4B (eIF4B). The ORF45/RSK signaling axis may contribute
to the enhancement of viral protein translation during lytic cycle.
The ORF45 protein also interacts with kinesin-2, a microtubule-
based motor protein, implicating that ORF45 protein is involved in
the transport of the viral capsid-tegument complexes along
microtubule ﬁlaments (Sathish et al., 2009). Despite theAAAA
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Protein extracts of HH-B2 cells treated with sodium butyrate or transfected with the
tibody.
P.-J. Chang et al. / Virology 442 (2013) 38–5040importance of ORF45 in the KSHV lytic cycle, its transcriptional
regulation is mostly unknown.
Although both ORF50 and ORF45 genes belong to the members
of the IE gene family, only ORF50 protein is sufﬁcient to trigger
the lytic cycle to completion in latently KSHV-infected PEL cells
(Gradoville et al., 2000; Sun et al., 1998). On the basis of this
notion, it is possible that ORF50 protein might have the capacity to
induce the ORF45 gene expression to facilitate the lytic-cycle
progression. In this study, we investigated the transcriptional
control of the ORF45 promoter and revealed that activation of
the promoter can be mediated through both ORF50-dependent
and ORF50-independent regulatory mechanisms.Results
Transcriptional mapping of the ORF45 gene
Previously, Zhu et al. (1999) have identiﬁed a 1.7-kb immediate-
early transcript encoding ORF45 protein in KSHV-infected PEL cell-954 
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Fig. 2. Responsiveness of 5′ deletion mutants of the ORF45 promoter to sodium butyrate
of the deletion constructs of the ORF45 promoter. All promoter regions shown in the dia
(ORF45p-FL) contains two core promoters (ORF45p and ORF46p; gray boxes) and two
deletion constructs in HH-B2 cells by SB treatment or by ORF50 overexpression. (C) Acti
overexpression. The fold activation of each reporter construct was calculated as the lucif
of stimuli. *po0.01 or #po0.05 compared to pGL3-B.lines after SB treatment. To study the transcriptional regulation of
the ORF45 gene, we ﬁrst mapped the 5′ transcriptional start site and
3′ polyadenylation cleavage site of the ORF45 mRNA by RACE
analysis. Total RNAs prepared from HH-B2 cells treated with SB
for 24 h were used in RACE assay. After DNA sequencing of the
ampliﬁed 5′-RACE products, three close transcriptional start sites of
the ORF45 mRNA were mapped at nucleotide (nt) 68,854, 68,860
and 68,863 of the KSHV genome (Fig. 1A and B). Among these
transcriptional start sites, the major one was located at nt 68,863,
which was designated as +1 in the study. There is a TATA-like
element (5-TTTCATCATCA) present in the upstream region of the
identiﬁed transcriptional start sites. In 3′-RACE analysis, the 3′
polyadenylation cleavage site of the ORF45 mRNA was mapped to
nt 67,325 located at 25 nt downstream of an AAUAAA hexamer
(Fig. 1A and B). Similar to the previous study by Zhu et al. (1999),
when the ORF45 coding regionwas used as a probe in Northern blot
analysis, a corresponding 1.7-kb ORF45 transcript was detected in
HH-B2 cells after SB treatment (Supplementary Fig. S1). As sug-
gested previously (Chang et al., 2010; Wang et al., 2012), a 2.7-kb
transcript corresponding to the ORF47+46+45 tricistronic mRNA+1 (68863)
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(SB) treatment and to ORF50 overexpression in HH-B2 and 293T cells. (A) Diagram
gramwere cloned into pGL3-Basic. As noted, the full-length ORF45 promoter region
RBP-Jκ-binding sites (black boxes). (B) Transcriptional activation of the ORF45p
vation of the ORF45p deletion constructs in 293T cells by SB treatment or by ORF50
erase activity in the presence of stimuli divided by luciferase activity in the absence
P.-J. Chang et al. / Virology 442 (2013) 38–50 41could be also detected in Northern blot analysis using the ORF45
probe. Sequence analysis revealed that the identiﬁed ORF45 mRNA
contains a short upstream open reading frame (uORF) preceding the
main ORF45 coding sequence (Fig. 1C). To determine whether the
ORF45 mRNA indeed encoded an ORF45 protein, a full-length ORF45
cDNAwas subcloned into an expression vector that encompasses three
copies of FLAG-tag DNA sequences at the 3′ end. After transfection of
the ORF45-expressing plasmid into 293T cells, a 72-kD protein could
be detected in Western blot analysis using either anti-ORF45 antibody
or anti-FLAG antibody (Fig. 1C). These results indicate that the
identiﬁed ORF45 transcript is a functional mRNA that encodes a
72-kD protein. The corresponding endogenous ORF45 protein could
be also detected in HH-B2 cells when compared to the transfected
ORF45 protein (Fig. 1D). Notably, multiple forms of ORF45 proteinwith
a lower molecular weight (o72 kDa) were also detected at later
stages of KSHV lytic cycle in HH-B2 cells (Fig. 1D and Fig. 4A),
implicating that different extents of the post-translational modiﬁca-
tions (e.g. phosphorylation) at ORF45 protein or the expression of
another unidentiﬁed ORF45 variants may occur in KSHV lytic cycle.-342
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Fig. 3. Activation of the ORF45 promoter by ORF50 protein is mediated through RBP-Jκ. (A
elements in the diagram were cloned into pE4luc, a luciferase reporter plasmid containin
ORF50 protein was determined in HH-B2 and 293T cells. (B) Binding of RBP-Jκ to the OR
with pCMV or pCMV-FLAG-RBP-Jκ were prepared and incubated with the DNA probe. T
excesses over the probe. An anti-FLAG antibody was used to supershift the DNA/protein
ORF45p-FL, ORF45p-D2 and ORF45p-D4 reporter constructs as shown in Fig. 2 were cotra
of each construct was determined by luciferase assay at 48-h post-transfection. (D) Ac
reporter plasmids were cotransfected with different effectors, including pCMV, pCMV-FLA
into OT11 cells. After 48-h post-transfection, activation of the reporter constructs by difORF50-dependent and ORF50-independent activation of the ORF45
promoter
To determine the critical regulatory elements of the ORF45
promoter (ORF45p), the ORF45p region from −954 to +121 and a
series of deletions were cloned into pGL3-Basic, a luciferase
reporter plasmid (Fig. 2A). The reporter activation of each con-
struct by SB treatment or by cotransfection with pCMV-FLAG-
ORF50 was measured in KSHV-positive (HH-B2) cells or in KSHV-
negative (293T) cells. As noted in Fig. 2A, the cloned ORF45p
regions did not include the short uORF found in the 5′-untrans-
lated region of the ORF45 mRNA. Actually, the presence or absence
of the uORF region in the ORF45p constructs displayed very similar
activation patterns in response to SB treatment or to ORF50
overexpression (Fig. 2 and Supplementary Fig. S2). To exclude
the potential post-transcriptional control (e.g. protein translation)
mediated by the uORF during the transcriptional analysis of the
ORF45 promoter, we used the set of the reporter constructs
without the uORF region.-110
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P.-J. Chang et al. / Virology 442 (2013) 38–5042In addition to the ORF45 core promoter, the cloned full-length
ORF45p-FL (−954/+121) region also encompassed an ORF46 core
promoter located around −562. Sequence analysis of the cloned
ORF45 promoter revealed that there are two consensus RBP-Jκ-
binding sites located from −647 to −641 and from −155 to −149
(Fig. 2A). In transient reporter assays, the ORF45p-FL reporter
displayed about 65-fold activation by SB in HH-B2 cells (Fig. 2B).
Similarly, the ORF45p-FL reporter was activated up to 64-fold by
ORF50 overexpression in HH-B2 cells (Fig. 2B), suggesting that the
ORF45 gene could be a downstream target of ORF50. Deletion
analysis of the ORF45 promoter showed that at least two regions
in the promoter were critical for either SB- or ORF50-mediated
activation in HH-B2 cells. The ﬁrst critical region was located from
-651 to -343, which contains an RBP-Jκ-binding site and the ORF46
core promoter. The second critical region was located between
−343 and −115, which also contains an RBP-Jκ-binding site.
Deletion of either positive region decreased the promoter activa-
tion by at least 20-fold (Fig. 2B). Interestingly, we found that after
removal of these two positive regions, activation of the ORF45
promoter by ORF50 was almost completely abolished. However, SB
treatment still retained some activity on the activation of the
ORF45 promoter (11.4 and 7.8-fold for ORF45p-D3 and ORF45p-D4
versus 2.5-fold for pGL3-B). These results suggest that SB treat-
ment may have additional effects on the ORF45p activation,
besides induction of the ORF50 expression in HH-B2 cells. To
further determine the effect of ORF50 overexpression or SB
treatment on the ORF45p activation, the reporter assay was carried
out in 293T cells. As shown in Fig. 2C, ORF50 protein could still
activate the ORF45 promoter in 293T cells. The ORF50-mediated
activation in 293T cells was similar to that in HH-B2 cells. SB
treatment was also able to signiﬁcantly activate the ORF45
promoter in 293T cells (Fig. 2C, left panel). Particularly, even
the shortest mutant ORF45p-D4 (−74/+121) still conferred a full
response to SB in 293T cells (Fig. 2C), suggesting that the SB-
responsive element may be located within the region between −74
and +121 (see below). Taken together, these results implicate that
the ORF45 promoter can be activated through both ORF50-
dependent and ORF50-independent pathways.Involvement of RBP-Jκ protein in the ORF45p activation by ORF50
As shown in Fig. 2, two positive regions located from −651 to
−343 and −343 to −115 of the ORF45 promoter were critical for
the ORF50 responsiveness. In our previous study, we have shown
that the RBP-Jκ-binding site (−647 to −641) within the ﬁrst
positive region is a functional ORF50 response element (ORF50110
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Fig. 4. Expression kinetics of viral lytic genes in HH-B2 cells and in HH-B2 (Tet-On-F-ORF
the expression levels of the ORF50, K8 and ORF45 genes at different time points in HH-B
ORF50, K8 and ORF45 genes were examined in HH-B2 (Tet-On-F-ORF50) cells after d
exogenously doxycycline-regulated ORF50 gene.RE) (Wang et al., 2012). In the second positive region from −343 to
−115, the minimal ORF50 RE remained to be characterized.
To deﬁne the minimal ORF50 RE in the ORF45p (−343/−115)
region, different pieces of the ORF45p region between −342 and
−110 were introduced into pE4luc, a reporter plasmid that con-
tains a heterologous adenovirus E4 promoter (Fig. 3A). When the
pE4luc reporter plasmid containing the ORF45p region from −342
to −110 was cotransfected with pCMV-FLAG-ORF50 in HH-B2 or in
293T cells, a 58- or 60-fold enhancement of luciferase activity was
detected (Fig. 3A, +RE1). The minimal ORF50 RE was mapped to a
35-bp element from −173 to −139, which contains an RBP-Jκ-
binding site (Fig. 3A, +RE-5). Mutation of the RBP-Jκ-binding site
in the RE-5 (−173 to −139) element completely abolished its
response to ORF50 (Fig. 3A, +RE-5(mt)). To determine the binding
of RBP-Jκ protein to the RE-5 element, protein extracts of 293T
cells transfected with pCMV or pCMV-FLAG-RBP-Jκ were used in
EMSAs (Fig. 3B). Competition analysis demonstrated that FLAG-
RBP-Jκ protein speciﬁcally bound to the RE-5 element. The DNA/
FLAG-RBP-Jκ complex formed in EMSA was also conﬁrmed by a
supershift assay with an anti-FLAG antibody (Fig. 3B). To further
examine the role of RBP-Jκ in the ORF45p activation by ORF50, we
analyzed the reporter activation in the RBP-Jκ knockout cell line
OT11. The parental wild-type mouse cell line OT13 was used as a
positive control for analyzing the ORF50-mediated transactivation.
The ORF45p-FL and ORF45p-D2 reporter plasmids shown in
Fig. 2A conferred 17- and 11-fold enhancement of luciferase
activity by ORF50 in OT13 cells (Fig. 3C). However, the ORF45p-
D4 reporter plasmid that lacks an RBP-Jκ-binding site failed to
respond to ORF50 in OT13 cells. In RBP-Jκ knockout OT11 cells,
neither of these reporter plasmids conferred a signiﬁcant response
to ORF50 (Fig. 3D). However, when the RBP-Jκ expressing plasmid
was introduced into OT11 cells, activation of the ORF45p-FL and
ORF45p-D2 constructs, but not the ORF45p-D4 construct, was
restored (Fig. 3D). These results indicate that binding of RBP-Jκ
protein to target DNA sites of the ORF45 promoter is critical for the
ORF50-mediated activation.Induction of endogenous ORF45 gene expression by ORF50 in HH-B2
cells
Next, we examined whether ORF50 could activate endogenous
ORF45 gene expression in the context of viral genome. A stable cell
line HH-B2 (Tet-On-F-ORF50) that contains an exogenously
doxycycline-regulated ORF50 gene in HH-B2 cells was used to
analyze the expression kinetics of viral lytic genes. When the HH-
B2 (Tet-On-F-ORF50) cells were treated with doxycycline, ORF50Hour:
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P.-J. Chang et al. / Virology 442 (2013) 38–50 43protein was abundantly expressed (Fig. 4B). Following the ORF50
overexpression, the expression of endogenous ORF45 gene was
signiﬁcantly induced with similar expression kinetics to the K8
gene, a downstream target gene of ORF50 protein. In a parallel
control experiment, the expression of ORF50, ORF45 and K8
proteins was examined in HH-B2 cells treated with SB (Fig. 4A).
As expected, all these tested viral genes were expressed at the
early stage during the lytic cycle induced by SB. Taken together,
these results conﬁrm that the ORF45 gene is a downstream target
of ORF50.
SB activates the ORF45 gene expression independently of ORF50
The ORF45 gene was previously classiﬁed as an IE gene in the
KSHV lytic cycle induced by SB (Zhu et al., 1999). Therefore, in
addition to the ORF50-mediated activation, the regulation of the
ORF45 gene could be controlled by an ORF50-independent
mechanism. To test this hypothesis, 293T cells harboring a wild-
type (BAC36) or an ORF50-deleted recombinant KSHV genome
(BAC36Δ50) were used to examine the ORF45 gene expression.
The BAC36 and BAC36Δ50 bacmids (Xu et al., 2005) were kindly
provided by Dr. Gregory Pari at University of Nevada and the
genome organization of both recombinant bacmids has been
conﬁrmed using Southern blot analysis (Supplementary Fig. S3).
The expression of the ORF45 gene could be abundantly activated
in 293T (BAC36) cells treated with SB. In the ORF50-knockout 293T
(BAC36Δ50) cells, SB treatment also signiﬁcantly increased the
ORF45 gene expression, although at lower levels compared to that
in 293T (BAC36) cells (Fig. 5B). Our results demonstrate that
activation of the ORF45 gene can be mediated through an
ORF50-independent mechanism. Despite the fact that SB can
induce the ORF45 gene independently of ORF50, full activation
of the ORF45 gene may require the presence of ORF50.
Deﬁning the SB-responsive elements in the ORF45 promoter
As described above, SB treatment could activate the ORF45
promoter in 293T cells (Fig. 2) and could induce endogenous
ORF45 gene expression in the ORF50-knockout 293T (BAC36Δ50)
cells (Fig. 5). To deﬁne the SB-responsive element in the ORF45
promoter, different truncated ORF45p reporter plasmids were
constructed. Compared to the full-length ORF45p (−954/+121)
reporter construct, the shorter ORF45p (−74/+121) construct still
conferred a full response to SB despite a lower basal promoter293T(BAC36)
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Removal of either region reduced the SB-mediated activation by
50–70% of the ORF45p (−74/+121) construct (Fig. 6B).
Sequence analysis has shown that the ORF45p (−74/+121)
region contains several putative binding sites for transcription
factors, including NF-1, NF-Y and Sp1 (Fig. 7A). Especially, the
putative NF-1- and NF-Y-binding sites were located within the
SB-responsive region between −74 and −41, and one of three
predictive Sp1-binding sites was located within another
SB-responsive region between +17 and +61. Point mutations at
the predictive transcription factor binding sites and the TATA box
were generated in the ORF45p (−74/+121) reporter construct
(Fig. 7B). The point mutants with mutations at the NF-1, NF-Y
and TATA sites displayed a reduced basal promoter activity
(Fig. 7C). However, the NF-1 and TATA mutants had almost normal
response to SB. The critical SB-responsive elements in the ORF45p
(−74/+121) region were mainly located at the NF-Y site and at the
ﬁrst Sp1 site (Sp1-I). Mutation at the NF-Y site or at the Sp1-I site
led to a decrease in the SB-mediated activation by 53% or by 56%.
Particularly, mutations at both NF-Y and Sp1-I sites completely
abolished the ORF45p activation by SB (Fig. 7C, mt-NF-Y/mt-SP1-I).
Binding of NF-Y and Sp1 to the ORF45 promoter in vitro and in vivo
To further determine whether NF-Y or Sp1 protein bound to the
predictive elements in the ORF45 promoter, we performed EMSA
experiments using the NF-Y- or Sp1-containing element as a
probe. The NF-Y probe element spanned from −65 to −41 could
form a DNA/protein complex in EMSA using total protein extract
from 293T cells (Fig. 8A). Addition of different cold “mutant”
competitors in the EMSA reaction showed that the protein
component of the DNA/protein complex speciﬁcally bound to the
3′ end of the probe, which corresponds to the NF-Y site (or CCAAT
box) (Fig. 8A). Since other family proteins including C/EBP could
also bind to the similar CAAT box, the consensus elements for
C/EBP and NF-Y were also used as cold competitors in EMSA.
As shown in Fig. 8B, only the consensus NF-Y-binding element, but
not the C/EBP-binding element or the mutated NF-Y element,
competed for the formation of the DNA/protein complex. Further-
more, antibody against NF-YA, a component of NF-Y (Dolﬁni et al.,
2009), sufﬁciently removed the DNA/protein complex (Fig. 8C).
These results suggest that NF-Y speciﬁcally binds to the CCAAT
box. To determine whether the NF-Y-binding element of the
ORF45 promoter was sufﬁcient to mediate the response to SB,
the ORF45p (−65/−41) element or a minimal NF-Y element (one or
two copies) was inserted into pE4luc (Fig. 8D). The minimal NF-Y
element was spanned from −52 to −41 of the ORF45 promoter.
The pE4luc reporter containing the ORF45p (−65/−41) element or
containing one or two copies of the minimal NF-Y element
signiﬁcantly conferred the SB-mediated activation in 293T cells
(4.3-, 2.7- or 5.1-fold versus 1.6-fold for the control). In contrast,
insertion of the corresponding NF-Y-mutated elements did not
mediate the reporter activation by SB.
The 45p-Sp1 element spanned from +9 to +36 of the ORF45
promoter was used as a probe in EMSAs to study the binding of
Sp1 protein. In EMSA reactions, the 45p-Sp1 probe element was
incubated with whole-cell protein extracts of 293T cells trans-
fected with pCMV, pCMV-FLAG-Sp1 or pCMV-FLAG-Sp1 (300–
785). The expressing plasmids pCMV-FLAG-Sp1 and pCMV-FLAG-
Sp1 (300–785) encode a full-length Sp1 and the DNA-binding
domain of Sp1, respectively. As shown in Fig. 9A, the overex-
pressed Sp1 proteins could directly bind the 45p-Sp1 probe and
addition of anti-FLAG antibody removed the speciﬁc DNA/protein
complex. Furthermore, only the wild-type cold competitor, but not
the mutant competitor, competed for the binding of Sp1 protein to
the probe (Fig. 9A, right panel). When the 45p-Sp1 element or aminimal Sp1 element (+16 to +28) was inserted into pE4luc, the
resulting plasmids permitted the reporter activation by SB (Fig. 9B).
However, inserting the corresponding Sp1-mutated elements did not
confer the SB-mediated activation. Taken together, our results
indicate that the SB-responsive elements of the ORF45 promoter
include both NF-Y and Sp1 sites.
To further conﬁrm the binding of NF-Y or Sp1 to the ORF45
promoter in the context of viral genome, we performed chromatin
immunopreciptiation (ChIP) experiments in HH-B2 cells. HH-B2
cells harvested at different time points (0, 4, 8, 16 and 24 h) after
SB treatment were subjected to Western blot analysis and ChIP
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P.-J. Chang et al. / Virology 442 (2013) 38–50 45assay simultaneously (Fig. 10). In the Western blot analysis, SB
treatment signiﬁcantly activated the expression of both ORF50 and
ORF45, but not NF-YA and Sp1, in HH-B2 cells. Using the semi-
quantitative PCR in ChIP assays, we found that NF-Y complex and
Sp1 speciﬁcally bound to the ORF45p region, but not the coding
regions of the ORF65 and PAN genes, even in the latent phase
(Fig. 10B). SB treatment did not further enhance the binding of Sp1
and NF-Y complex to the ORF45 promoter. However, the extent of
acetylation of histone H4 on the ORF45 promoter or other viral
genome regions was dramatically enhanced after 4 h treatment
with SB (Fig. 10B). These results indicate that chromatin remodel-
ing induced by SB may facilitate the activation of the ORF45 gene.
The association between speciﬁc transcriptional proteins and the
ORF45 promoter at different time points were also conﬁrmed by
quantitative real-time PCR (Fig. 10C).Discussion
Both ORF50 and ORF45 genes belong to the members of the
IE gene family, which were previously characterized in latently
KSHV-infected PEL cells after SB treatment (Zhu et al., 1999). The
transcriptional regulation of the ORF50 gene has been extensivelyinvestigated (Chang et al., 2011; Lan et al., 2005; Lu et al., 2003;
Ye et al., 2005). However, the transcriptional control of the ORF45
gene remains largely unknown. In this report, we mapped the 5′
transcriptional start site and 3′ polyadenylation cleavage site of the
ORF45 transcript and examined the molecular mechanisms under-
lying the transcriptional control of the ORF45 gene. The major
transcriptional start site and polyadenylation cleavage site of the
ORF45 gene were mapped at nt 68,863 and at nt 67,325, respec-
tively (Fig. 1). Based on the KSHV genome organization and our
previous studies (Chang et al., 2010; Wang et al., 2012), we found
that the transcripts initiated from ORF45p, ORF46p and ORF47p
overlap each other (Fig. 1). In the identiﬁed ORF45 mRNA, a small
uORF that would encode seven amino acids is located upstream of
the ORF45 coding region. The presence of the uORF in the ORF45
mRNA still allows its protein expression in cells (Fig. 1C). However,
whether the uORF can encode a functional peptide or whether the
uORF in the mRNA modulates the translational efﬁciency of ORF45
protein may need to be further characterized. Another important
aspect in the study is to elucidate the transcriptional regulation
of the ORF45 gene. We show that the ORF45 gene promoter is
activated not only by SB but also by ORF50 protein. Both ORF50-
dependent and ORF50-independent (or SB-induced) mechanisms
are discussed below.
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Among the KSHV immediate-early-lytic proteins, only ORF50
protein is sufﬁcient to initiate the lytic cascade to completion
in latently KSHV-infected cells. Consistent with this notion, our
results displayed that the ORF45 gene could be a downstream
target of ORF50. In transient reporter assays, the ORF45 promoter
was activated by ORF50 in either KSHV-positive or KSHV-negative
cells (Figs. 2 and 3). Furthermore, ectopic overexpression of ORF50
in PEL cells sufﬁciently induced endogenous ORF45 gene expres-
sion (Fig. 4). Previously, Chen et al. (2009) have identiﬁed a set of
ORF50-binding regions present in KSHV genome using chromatin
immunoprecipitation assay coupled with a KSHV whole-genome
tiling microarray (Chen et al., 2009). One of the identiﬁed ORF50-
binding regions (∼480 bp) is located within the ORF45 promoter.
However, they did not further conﬁrm the activation of the ORF45
promoter by ORF50 and further deﬁne a minimal ORF50-binding
site. After deletion analysis of the ORF45 promoter, two ORF50-
responsive regions encompassing a consensus RBP-Jκ-binding site,
GTGGGAA, were found in the ORF45 promoter (Fig. 2). In addition
to the core RBP-Jκ-binding sequence, both RBP-Jκ sites in the
ORF45 promoter also share an additional conserved cytosine (C)
at 5′ ﬂanking region, which is a feature of many knownORF50-responsive RBP-Jκ sites (Persson and Wilson, 2010). The
presence of the conserved cytosine residue ﬂanking the core RBP-
Jκ-binding sequence may contribute to a higher-afﬁnity binding
site (Persson and Wilson, 2010). The distal RBP-Jκ-binding element
located near the ORF46 core promoter has previously been
reported to be an ORF50 RE that regulates the ORF46 gene
promoter (Wang et al., 2012). Our present study found that the
same RBP-Jκ-binding site also controls the ORF45p activation by
ORF50. The proximal RBP-Jκ-binding element spanned from −173
to −139 was a newly identiﬁed ORF50 RE. Binding of RBP-Jκ
protein to the element was strongly correlated with the promoter
activation by ORF50 (Fig. 3). Thus, we conclude that ORF50
activates the ORF45 gene through RBP-Jκ. Noteworthily, the RBP-
Jκ-dependent regulatory mechanism can also be operated on two
adjacent genes, ORF47 and ORF46 (Chang et al., 2010; Wang et al.,
2012). Binding of RBP-Jκ protein to the promoter regions (ORF47p,
ORF46p and ORF45p) in the ORF47/46/45 gene cluster is essential
for the activation of these genes. In addition to the transcriptional
regulation occurring in the ORF47/46/45 gene cluster, the RBP-Jκ-
binding sites within the region are also shown to mediate the
auto-regulation of the ORF50 promoter (Lan et al., 2005; Lu et al.,
2012). These results strongly implicate that a wide array of viral
lytic genes is controlled through the same RBP-Jκ-binding sites
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shown that cohesin, a chromatin-organizing complex, represses
the KSHV lytic cycle by interacting with an insulator protein CTCF
to several immediate-early control regions of viral genome (Chen
et al., 2012). In addition to the ORF50 gene locus, the most
prominent control region bound by CTCF-cohesin is within the
ORF47/46/45 locus. Interestingly, multiple RBP-Jκ sites in the
ORF47/46/45 locus were found to overlap or in close proximity
to the CTCF-cohesin binding sites. Whether RBP-Jκ protein plays
some roles in the cohesin-mediated lytic gene repression during
latency remains to be addressed.
The NF-Y and Sp1-binding sites in the ORF45 promoter confers the
response to SB
SB, an inhibitor of histone deacetylases (HDACs), is a well-
known inducing agent for the KSHV lytic cycle (Miller et al., 1997;
Zhu et al., 1999). In the absence of ORF50 protein, we found that SB
treatment could still activate the ORF45 gene promoter (Fig. 2C)
and induce endogenous ORF45 gene expression (Fig. 5B). After
serial deletions of the ORF45 promoter, two SB-responsive ele-
ments were identiﬁed within −74 to −41 and +17 to +61 (Fig. 6).
Further point mutation analysis exhibited that an inverted CCAAT
box and an Sp1-binding site are essential for SB-mediated activa-
tion (Figs. 7–9). Speciﬁc binding of NF-Y and Sp1 to the CCAAT box
and Sp1-binding site of the ORF45 promoter has been demon-
strated in vitro and in vivo (Figs. 8–10). NF-Y is a well-
characterized CCAAT box-binding protein complex composed of
NF-YA, NF-YB and NF-YC (Dolﬁni et al., 2009). Binding of NF-Y to
speciﬁc promoters often contributes to the basal promoter activity
(Dolﬁni et al., 2009; Xu et al., 2012). Sp1 protein is a zinc ﬁnger
DNA-binding protein, which is known to regulate numerous viral
or cellular genes in cells (Chu and Ferro, 2005). Studies on the SB-responsive genes in cells have revealed that the Sp1/Sp3-binding
site appears to be the most common sequence in the identiﬁed SB
response elements (Davie, 2003). Such cellular SB-responsive
genes include galectin1, G alpha(i2), IGF-binding protein 3 and
p21waf1/Cip1 (Davie, 2003; Lu and Lotan, 1999; Walker et al., 2001;
Yang et al., 2001). In addition to cellular genes, studies on the
KSHV ORF50 gene have also revealed that an Sp1/Sp3-binding site
in the promoter is required for the response to SB (Lu et al., 2003;
Ye et al., 2005). These ﬁndings implicate that the association of
Sp1or Sp3 with HDACs or histone acetyltransferases on target
promoter regions may be a general regulatory mechanism induced
by SB. In addition to Sp1-binding site, emerging evidence has
suggested that NF-Y-binding site present in certain gene promo-
ters is also important for responding to SB or trichostatin A (TSA),
another inhibitor of HDACs. The importance of the Sp1 and NF-Y
proteins that cooperatively regulate the gene activation by HDAC
inhibitors has been demonstrated in several cellular genes, includ-
ing multidrug protein 1 (MDR1), transforming growth factor β type
II receptor, and heat shock protein 70 (Hu et al., 2000; Huang et al.,
2005; Jin and Scotto, 1998; Marinova et al., 2011). Similar to the
regulation of these cellular genes, both NF-Y and Sp1-binding sites
in the ORF45 promoter are also critical for responding to SB.
Particularly, our results showed that the individual NF-Y or Sp1-
binding element from the ORF45 promoter could independently
confer the response to SB (Figs. 8 and 9). Although binding of NF-Y
and Sp1 to the ORF45 promoter was required for the ORF45p
activation, SB treatment did not further increase their DNA-
binding activity and their protein expression (Fig. 10). As suggested
above, it is possible that association of NF-Y or Sp1 with HDACs or
histone acetyltransferases on the promoter region may be respon-
sible for controlling the promoter activation. Whether speciﬁc co-
activators are required for the activation of the ORF45 promoter in
response to SB needs to be further determined.
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activated through both ORF50-dependent and ORF50-independent
(or SB-mediated) pathways. Activation of the ORF45 gene by
ORF50 requires the cellular RBP-Jκ protein, whereas both NF-Y
and Sp1 are involved in the SB-mediated activation. Although
there are at least four IE genes expressed in the lytic cycle, our
ﬁndings imply that ORF50 protein may have a general potential to
further stimulate the expression of other IE genes such as its own
gene and the ORF45 gene. Understanding the detailed transcrip-
tional control of the ORF45 gene may provide further insights into
the regulatory network of KSHV IE genes.Materials and methods
Cell cultures and transfections
HH-B2 is a primary effusion lymphoma cell line cultured in
RPMI 1640 medium supplemented with 15% fetal bovine serum
(FBS) (Gradoville et al., 2000). HH-B2 (Tet-On-F-ORF50) is a stable
HH-B2 cell clone with a doxycycline-regulated ORF50 gene (Wang
et al., 2010). The HH-B2 (Tet-On-F-ORF50) cells were maintained
in the RPMI 1640 medium containing 15% FBS, 100 μg/ml G418,
and 400 μg/ml hygromycin. For induction of the exogenous
ORF50 protein in HH-B2 (Tet-On-F-ORF50) cells, doxycycline
(Sigma) was added in 1 μg per ml. A 293T is derived from human
embryonic kidney cells transformed with the E1 region of adeno-
virus and the simian virus 40 T antigen. The 293T cells were
cultured in high-glucose DMEM supplemented with 10% FBS. Both
293T (BAC36) and 293T (BAC36Δ50) cells harboring KSHV bacmids
were maintained in the medium with 200 μg/ml hygromycin.
For chemical induction, sodium butyrate (3 mM), TPA (30 ng/ml)
or both were added to the medium. Mouse RBP-Jκ−/− (OT11:
RCB1926) and wild type (OT13: RCB1927) embryonic ﬁbroblast
cell lines (Kato et al., 1997) were provided by the RIKEN BRC
through the National Bio-Resource Project of the MEXT, Japan.
The OT11 and OT13 cells were grown in high-glucose DMEM
supplemented with 10% FBS and 100 U/ml of mouse interferon
gamma. All transfection experiments were conducted with Lipo-
fectamine 2000 according to the manufacturer's instruction
(Invitrogen).Rapid ampliﬁcation of cDNA ends (RACE)
The 5′ transcriptional start site and 3′ polyadenylation cleavage
site of the ORF45 gene were mapped using the GeneRacer kit
(Invitrogen). HH-B2 cells were treated with 3 mM sodium butyrate
for 24 h and the total RNAs from these cells was extracted. Two
micrograms of total RNAs were treated with calf intestinal phos-
phatase to remove 5′ phosphates of the truncated mRNA and non-
mRNA, and then treated with tobacco acid pyrophosphatase to
remove the 5′cap of full-length mRNAs. An RNA linear oligonu-
cleotide was subsequently ligated to the RNA samples by T4 RNA
ligase. The resulting mRNAs were reversely transcribed into the
ﬁrst-strand cDNAs using either random primers or an oligo(dT)
primer. PCR ampliﬁcation was carried out using gene speciﬁc
primers and the adaptor-speciﬁc primers provided in the kit. To
amplify the 5′ end of the ORF45 cDNA, the ORF45-speciﬁc primers
used in the initial PCR and nested PCR were 5′-CCTCATCCTCGT-
CATATTCAGATTCG and 5′-GCCTGCCAAATCCTGGAAGTGATG,
respectively. The ORF45-speciﬁc primer used for amplifying the
3′ polyadenylation region of the ORF45 gene was 5′-CCAGAAGCG-
CAAAAGGCAGTCTACC. The ampliﬁed DNA fragments were then
cloned and sequenced.Plasmid construction
The ORF45-expressing plasmid was constructed by inserting an
ORF45 cDNA region from nt 68,863 to 67,353 of KSHV genome into
pCMV-3Tag-3 (Stratagene) digested with HindIII and XhoI.
The ORF45 cDNA fragment was obtained by PCR ampliﬁcation.
To construct the ORF45p reporter plasmids, the ORF45p regions
were ampliﬁed by PCR and cloned into pGL3-Basic (Promega) at
NheI and HindIII sites. The plasmids including pE4luc, pCMV-
FLAG-ORF50, pCMV-FLAG-RBP-Jκ, pCMV-FLAG-Sp1 (1–785) and
pCMV-FLAG-Sp1 (300–785) were described previously (Chang
et al., 2005b, 2008; Wang et al., 2012). To deﬁne the ORF50
response element or butyrate-responsive element, the double-
stranded oligonucleotides or PCR-ampliﬁed DNA fragments were
cloned into pE4luc digested with NheI and XhoI. Point mutations
were introduced into the ORF45 promoter using the QuickChange
site-directed mutagenesis kit (Stratagene).
Luciferase assays
HH-B2, 293T, OT11 and OT13 cells (7105) were transfected
with a ﬁxed amount (0.8 μg) of plasmid DNA that includes the
reporter and effector plasmids. The reporter assays were carried
out according to manufacturer's protocol for the luciferase repor-
ter assay system (Promega). Fold activation was calculated as
luciferase activity in the presence of the inducing agents divided
by that in the absence of the inducing agents. The value of fold
activation represents at least three independent experiments with
duplicate samples in each transfection.
Electrophoretic mobility shift assay (EMSA)
Total protein extracts for EMSAs were prepared from 293T cells.
Cells were lysed in cell lysis buffer (0.42 M NaCl, 20 mM HEPES
[pH 7.5], 25% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM dithio-
threitol, 1 mM phenylmethylsulfonyl ﬂuoride, and 2 μg/ml aproti-
nin). Lysates were centrifuged at 90,000 rpm at 4 1C for 15 min in a
benchtop ultracentrifuge and supernatants were harvested and
stored at −80 1C. Annealed double-stranded oligonucleotides were
end-labeled with biotin-11-UTP using terminal deoxynucleotidyl
transferase (PIERCE). Binding reactions contained 10 μg of total
protein extract in a solution containing 10 mM HEPES (pH 7.5),
50 mM NaCl, 2 mM MgCl2, 2.5 μM ZnSO4, 0.5 mM EDTA, 1 mM
dithiothreitol, 15% glycerol and 0.5 μg poly(dIdC) in a total volume
of 20 μl. In the competition analysis, unlabeled competitor DNA
was added to the initial reaction mix. For removing or super-
shifting the protein/DNA complex formed in EMSA, speciﬁc or
control antibodies were added in the EMSA reactions. Antibodies
to FLAG (M2, Sigma), NF-1 (sc-5567X, Santa Cruz), NF-YA (sc-
10779X, Santa Cruz) and actin (MAB101; Chemicon) were obtained
commercially.
Western blot analysis
Cell protein extracts were prepared in cell lysis buffer (0.42 M
NaCl, 20 mM HEPES [pH 7.5], 25% glycerol, 1.5 mM MgCl2, 0.2 mM
EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl ﬂuoride,
and 2 μg/ml aprotinin). Protein extracts were mixed with 3
sodium dodecyl sulfate (SDS) gel loading buffer and boiled for
5 min before proteins were resolved on 8–10% polyacrylamide gel.
The proteins were then transferred onto a PVDF membrane (Bio-
Rad) and probed with speciﬁc antibodies. The rabbit polyclonal
antibody against ORF50 protein was generated in our laboratory
using bacterially produced ORF50 protein (aa 1–590) as an anti-
gen. Antibodies to K8 (sc-57889; Santa Cruz), ORF45 (sc-53883;
Santa Cruz), NF-YA (sc-10779, Santa Cruz), Sp1 (sc-59; Santa Cruz),
P.-J. Chang et al. / Virology 442 (2013) 38–50 49actin (MAB101; Chemicon) and FLAG (M2; Sigma) were obtained
commercially.
Chromatin immunoprecipitation (ChIP) assay
HH-B2 cells treated with 3 mM sodium butyrate for different
periods were used in ChIP assay as described previously (Wang
et al., 2010). The chromatin complex immunoprecipitated by
antibodies to NF-YA (sc-10779, Santa Cruz), Sp1 (sc-59; Santa
Cruz), actin (sc-1616; Santa Cruz) or acetyl-histone H4 (06-866;
Upstate) were harvested and then analyzed by semi-quantitative
PCR or by real-time PCR according to MIQE guidelines (Bustin
et al., 2009). The individual primer sequences for PCR ampliﬁca-
tion were following: 5′-CAGGTGTTTCTGTGCGTTTATGAGC and 5′-
CTACTAAACACAGTTTTGACGGTGG for the ORF45 promoter; 5′-
GTTTCTGATCCCTAAGGGTCTGCAG and 5′-CTGGATCAGGGAAA-
TATGTCGCAGG for the ORF65 coding region; 5′-TGCATTGGATT-
CAATCTCCAGGCCA and 5′-GTAGTGCACCACTGTTCTGATACAC for
the PAN coding region. The cycle numbers used in the semi-
quantitative PCR were 27–30 cycles. For quantitative real-time
PCR, the reaction (25 μl) contained 1 μl of the immunoprecipited
DNA, 2.5 μmol/l PCR primers, and 2X iQ SYBR Green Supermix
(Bio-Rad, Hercules, CA). All real-time PCR assays were performed
in duplicate from two independent treatments.
Statistical analysis
Data shown in the study were mean values with standard
deviations. The signiﬁcance of differences between groups was
analyzed by Student’s t test. Po0.05 was considered statistically
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